Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16897446 | 0.87 | PKM (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11794766 | 0.87 | F2 (0.49) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11798964 | 0.84 | CA1 (0.43) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL7127537 | 0.83 | ALDH1A1 (0.60) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL20085600 | 0.83 | CA1 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL8634995 | 0.82 | STAT3 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9247417 | 0.81 | MAPT (0.48) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3179301 | 0.81 | F2 (0.49) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL7128931 | 0.81 | CA1 (0.56) | CA1CA2CA12CA9CA6 | |
| SCHEMBL4951056 | 0.81 | ALDH1A1 (0.54) | CA1CA2CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024069007-A2 | IMMUNOSUPPRESSIVE COMPOUNDS | UNIVERSITÄT BASEL (CH) | 2024-04-04 | — | — | WO | disclosed |
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-3262048-A1 | ANTIVIRAL COMPOUNDS | Alios Biopharma, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9783512-B2 | Bicyclic methylene aziridines and reactions thereof | WISCONSIN ALUMI RESEARCH FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-3036220-A1 | ANTIVIRAL COMPOUNDS | Alios Biopharma, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-03-17 | — | — | US | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20130079511-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2013033245-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8304553-B2 | Method of forming oseltamivir and derivatives thereof | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-11-06 | — | — | US | disclosed |
| US-20120101271-A1 | DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES | NATIONAL SCIENCE FOUNDATION | 2012-04-26 | — | — | US | disclosed |
| US-7956193-B2 | Intramolecular C-H amination with sulfonyl azides | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-01-27 | — | — | US | disclosed |
| US-20100063277-A1 | Intramolecular C-H amination with sulfonyl azides | NATIONAL SCIENCE FOUNDATION | 2010-03-11 | — | — | US | disclosed |
| WO-2009078813-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2009-06-25 | — | — | WO | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA1 4791/4885CA2 3830/4885MMP1 4107/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CA1 4791/4885CA2 3830/4885MMP1 4107/4885 |
| US-20100063277-A1 | Intramolecular C-H amination with sulfonyl azides | TST, TIMM9, PPOX | CA1 2591/4885CA2 1273/4885MMP1 4650/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CA1 4791/4885CA2 3830/4885MMP1 4107/4885 |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | AAAS, CYCS, AOC2 | CA1 3618/4885CA2 4187/4885MMP1 3845/4885 |
| US-20110021762-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | AOC1, ALK, ALDH3A1 | CA1 632/4885CA2 401/4885MMP1 1571/4885 |
| US-20120101271-A1 | DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES | DOHH, AOC1, ESD | CA1 777/4885CA2 745/4885MMP1 3980/4885 |
| US-20130079511-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | AAAS, CYCS, AOC2 | CA1 3618/4885CA2 4187/4885MMP1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.